^
Association details:
| Biomarker: | PIK3CA wild-type + PTEN wild-type |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | pazopanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database
Published date:
12/20/2023
Excerpt:
The RR was lowest for eribulin in an MDM2-amplification cluster (OR: 0.4; p = 0.03) and highest in a TERT-mutation cluster (OR: 3.0; p = 0.03). The RR was highest for pazopanib in a PIK3CA/PTEN-wild type cluster (OR: 2.1; p = 0.03).
DOI:
10.1111/cas.16050
